Advertisement
ResearchIn-Press PreviewImmunologyOncology
Open Access |
10.1172/JCI199056
1Department of Cancer Sciences, Cleveland Clinic, Cleveland, United States of America
Find articles by Zhou, F. in: PubMed | Google Scholar
1Department of Cancer Sciences, Cleveland Clinic, Cleveland, United States of America
Find articles by Pang, L. in: PubMed | Google Scholar
1Department of Cancer Sciences, Cleveland Clinic, Cleveland, United States of America
Find articles by Liu, Y. in: PubMed | Google Scholar
1Department of Cancer Sciences, Cleveland Clinic, Cleveland, United States of America
Find articles by Khan, F. in: PubMed | Google Scholar
1Department of Cancer Sciences, Cleveland Clinic, Cleveland, United States of America
Find articles by Chen, P. in: PubMed | Google Scholar
Published March 17, 2026 - More info
Glioblastoma (GBM) is a highly aggressive brain tumor characterized by extensive crosstalk between glioblastoma stem cells (GSCs) and immunosuppressive microglia, with our previous work identifying CLOCK and TFPI2 as key regulators of this interaction. Here, we uncover a ‘symbiotic exclusivity’ pattern between CLOCK and TFPI2, showing that despite mutually exclusive amplifications, they sustain symbiotic regulatory interactions in GBM. The CLOCK-BMAL1 complex transcriptionally upregulates TFPI2, while TFPI2-driven hypoxia inducible factor 1 alpha (HIF1a) signaling activates nuclear factor kappa B (NF-kB) P65 to upregulate the CLOCK-BMAL1 complex, creating a positive feedback loop to promote stemness, immunosuppression, and tumor progression. Disrupting the CLOCK-TFPI2 interplay through dual inhibition of their downstream effectors reduces GSC stemness and immunosuppressive microglia, activates antitumor immunity, and synergizes with anti-PD1 therapy to achieve complete tumor regression in 50-62.5% of tumor-bearing mice. This study uncovers a promising therapeutic strategy for a broader subset of GBM patients with high expression of either CLOCK or TFPI2, and provides a framework for identifying 'symbiotic exclusivity' genes in cancer.